At AlphaMeld® Corporation, we are agnostic to disease areas, leveraging our cutting-edge-AI-based platform to uncover innovation across a broad range of therapeutic domains. Powered by over a decade of curated and connected datasets, AlphaMeld® identifies alpha signals of innovation for targets, drugs, and healthcare technologies. With capabilities spanning small molecules, biologics, cell and gene therapies, and more, we ensure no therapeutic modality or disease area is beyond reach.

Recently, we have introduced a focused effort in obesity research, leveraging AI to address unmet needs in this critical area. Our advanced obesity disease model identifies novel biological pathways and therapeutic targets, aiming to enhance fat loss quality, address gastrointestinal motility challenges, and improve weight loss maintenance to complement existing GLP-1 therapies. This marks a new chapter in our mission to transform drug discovery and create impactful therapies for patients worldwide.